Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials.
INTRODUCTION:18Fluorodeoxyglucose (FDG) positron emission tomography (PET) uptake in the artery wall correlates with active inflammation. However, in part due to the low spatial resolution of PET, variation in the apparent arterial wall signal may be influenced by variation in blood FDG activity tha...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5683610?pdf=render |
id |
doaj-ec51e24d027d400cbc9f72a0a797a73c |
---|---|
record_format |
Article |
spelling |
doaj-ec51e24d027d400cbc9f72a0a797a73c2020-11-24T21:34:17ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-011211e018799510.1371/journal.pone.0187995Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials.Mark A AhlmanDavis M VigneaultVeit SandfortRoberto Maass-MorenoJenny DaveAhmed SadekMarissa B MallekMariana A F SelwanessPeter HerscovitchNehal N MehtaDavid A BluemkeINTRODUCTION:18Fluorodeoxyglucose (FDG) positron emission tomography (PET) uptake in the artery wall correlates with active inflammation. However, in part due to the low spatial resolution of PET, variation in the apparent arterial wall signal may be influenced by variation in blood FDG activity that cannot be fully corrected for using typical normalization strategies. The purpose of this study was to evaluate the ability of the current common methods to normalize for blood activity and to investigate alternative methods for more accurate quantification of vascular inflammation. MATERIALS AND METHODS:The relationship between maximum FDG aorta wall activity and mean blood activity was evaluated in 37 prospectively enrolled subjects aged 55 years or more, treated for hyperlipidemia. Target maximum aorta standardized uptake value (SUV) and mean background reference tissue activity (blood, spleen, liver) were recorded. Target-to-background ratios (TBR) and arterial maximum activity minus blood activity were calculated. Multivariable regression was conducted, predicting uptake values based on variation in background reference and target tissue FDG uptake; adjusting for gender, age, lean body mass (LBM), blood glucose, blood pool activity, and glomerular filtration rate (GFR), where appropriate. RESULTS:Blood pool activity was positively associated with maximum artery wall SUV (β = 5.61, P<0.0001) as well as mean liver (β = 6.23, P<0.0001) and spleen SUV (β = 5.20, P<0.0001). Artery wall activity divided by blood activity (TBRBlood) or subtraction of blood activity did not remove the statistically significant relationship to blood activity. Blood pool activity was not related to TBRliver and TBRspleen (β = -0.36, P = NS and β = -0.58, P = NS, respectively). CONCLUSIONS:In otherwise healthy individuals treated for hyperlipidemia, blood FDG activity is associated with artery wall activity. However, variation in blood activity may mask artery wall signal reflective of inflammation, which requires normalization. Blood-based TBR and subtraction do not sufficiently adjust for blood activity. Warranting further investigation, background reference tissues with cellular uptake such as the liver and spleen may better adjust for variation in blood activity to improve assessment of vascular activity.http://europepmc.org/articles/PMC5683610?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mark A Ahlman Davis M Vigneault Veit Sandfort Roberto Maass-Moreno Jenny Dave Ahmed Sadek Marissa B Mallek Mariana A F Selwaness Peter Herscovitch Nehal N Mehta David A Bluemke |
spellingShingle |
Mark A Ahlman Davis M Vigneault Veit Sandfort Roberto Maass-Moreno Jenny Dave Ahmed Sadek Marissa B Mallek Mariana A F Selwaness Peter Herscovitch Nehal N Mehta David A Bluemke Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials. PLoS ONE |
author_facet |
Mark A Ahlman Davis M Vigneault Veit Sandfort Roberto Maass-Moreno Jenny Dave Ahmed Sadek Marissa B Mallek Mariana A F Selwaness Peter Herscovitch Nehal N Mehta David A Bluemke |
author_sort |
Mark A Ahlman |
title |
Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials. |
title_short |
Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials. |
title_full |
Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials. |
title_fullStr |
Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials. |
title_full_unstemmed |
Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials. |
title_sort |
internal tissue references for 18fluorodeoxyglucose vascular inflammation imaging: implications for cardiovascular risk stratification and clinical trials. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2017-01-01 |
description |
INTRODUCTION:18Fluorodeoxyglucose (FDG) positron emission tomography (PET) uptake in the artery wall correlates with active inflammation. However, in part due to the low spatial resolution of PET, variation in the apparent arterial wall signal may be influenced by variation in blood FDG activity that cannot be fully corrected for using typical normalization strategies. The purpose of this study was to evaluate the ability of the current common methods to normalize for blood activity and to investigate alternative methods for more accurate quantification of vascular inflammation. MATERIALS AND METHODS:The relationship between maximum FDG aorta wall activity and mean blood activity was evaluated in 37 prospectively enrolled subjects aged 55 years or more, treated for hyperlipidemia. Target maximum aorta standardized uptake value (SUV) and mean background reference tissue activity (blood, spleen, liver) were recorded. Target-to-background ratios (TBR) and arterial maximum activity minus blood activity were calculated. Multivariable regression was conducted, predicting uptake values based on variation in background reference and target tissue FDG uptake; adjusting for gender, age, lean body mass (LBM), blood glucose, blood pool activity, and glomerular filtration rate (GFR), where appropriate. RESULTS:Blood pool activity was positively associated with maximum artery wall SUV (β = 5.61, P<0.0001) as well as mean liver (β = 6.23, P<0.0001) and spleen SUV (β = 5.20, P<0.0001). Artery wall activity divided by blood activity (TBRBlood) or subtraction of blood activity did not remove the statistically significant relationship to blood activity. Blood pool activity was not related to TBRliver and TBRspleen (β = -0.36, P = NS and β = -0.58, P = NS, respectively). CONCLUSIONS:In otherwise healthy individuals treated for hyperlipidemia, blood FDG activity is associated with artery wall activity. However, variation in blood activity may mask artery wall signal reflective of inflammation, which requires normalization. Blood-based TBR and subtraction do not sufficiently adjust for blood activity. Warranting further investigation, background reference tissues with cellular uptake such as the liver and spleen may better adjust for variation in blood activity to improve assessment of vascular activity. |
url |
http://europepmc.org/articles/PMC5683610?pdf=render |
work_keys_str_mv |
AT markaahlman internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials AT davismvigneault internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials AT veitsandfort internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials AT robertomaassmoreno internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials AT jennydave internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials AT ahmedsadek internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials AT marissabmallek internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials AT marianaafselwaness internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials AT peterherscovitch internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials AT nehalnmehta internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials AT davidabluemke internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials |
_version_ |
1725950175013240832 |